"临床研究表明，甲磺酸普雷福韦片在降低乙肝表面抗原水平方面表现突出，有助于提升临床治愈 比例，从而切实降低肝硬化、肝癌的长期发生风险。"新通药物副总经理刘世峰介绍，"我国慢性乙肝患 者数量庞大，疾病负担重。甲磺酸普雷福韦片进入国家医保药品目录后，将在市场上迅速放量，极大提 升药物可及性，让更多患者能用得上、用得起最新最前沿的治疗方案。" 12月7日，国家医保局、人力资源社会保障部公布《国家基本医疗保险、生育保险和工伤保险药品 目录（2025年）》，全国共有50种1类创新药进入目录。其中，由陕西省级上市后备企业西安新通药物 研究股份有限公司研发的甲磺酸普雷福韦片（商品名称：新舒沐）是全省唯一一个进入国家医保药品目 录的1类创新药，将于2026年1月1日起执行医保支付标准。 "陕西上市后备企业在资本市场的影响力将进一步扩大。"陕西资本市场服务中心相关负责人表示， 将持续完善对生物医药等战略性新兴产业上市后备企业的培育与服务机制，引导更多"耐心资本"助力本 土创新。（记者：孙丹） 1类创新药指未在国内外上市销售的药品，代表我国药品注册分类中药物创新的最高水平。长期以 来，临床一线乙肝治疗药主要为进口药和仿制药。甲磺 ...

Core Insights - Shaanxi is leveraging its advantages to drive high-quality development through innovation, integrating technological and industrial innovation to build a modern industrial system [1][5] - The province is witnessing a surge in technology-driven enterprises and the transformation of scientific research achievements into marketable products [1][5] Group 1: Technological Innovations - Intelligent non-destructive testing technology developed by Xi'an Shuhua Information Technology Co., Ltd. can detect micro-defects in industrial equipment with a speed 40 times faster than traditional methods, achieving nearly 100% detection rate for defects [2][4] - The company has rapidly become a leader in multi-modal AI quality inspection solutions in the high-end manufacturing sector, supported by strategic partnerships and resource allocation from local initiatives [4][5] Group 2: Policy and Support - Shaanxi is implementing three reform policies to enhance the transformation of scientific achievements into products, focusing on investment, talent, and support for technology-driven enterprises [4][5] - By 2024, Shaanxi will have 201 pilot units for these reforms, with over 10.6 million scientific achievements recorded and 3.6 million successfully transferred to market applications [5] Group 3: Pharmaceutical Innovations - Xi'an New Tong Pharmaceutical Research Co., Ltd. has developed the world's first targeted innovative drug for hepatitis B, marking a significant breakthrough for Shaanxi's pharmaceutical industry [6][7] - The drug has shown superior efficacy compared to existing imported treatments, highlighting the province's potential in biopharmaceutical innovation [7][8] Group 4: Emerging Industries - Shaanxi is focusing on developing strategic emerging industries such as new energy vehicles and solar photovoltaics, aiming to enhance its industrial chain and promote high-quality growth [9][10] - The province's strategic emerging industries have seen rapid growth, contributing to the formation of a modern industrial system [9][10] Group 5: Entrepreneurial Ecosystem - The supportive policies in Shaanxi have fostered a conducive environment for innovation and entrepreneurship, leading to the rapid growth of technology-based enterprises [11][12] - The number of high-tech enterprises in Shaanxi has been growing at over 30% annually, indicating a robust innovation ecosystem [12]